Anthropic plans IPO while pushing into drug research
The AI company, which is seeking a Nasdaq listing under the ticker ANT, has shared early findings from work with six research partners.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
Anthropic is planning an initial public offering on Nasdaq under the ticker ANT. The company has shared early findings from its drug programs with six partners, including Bristol Myers Squibb. It has also been running its own drug programs after acquiring a one-person biotech.
Why it matters
Anthropic says it hopes its AI systems will match top human experts across scientific fields.
Coverage
- Johns Hopkins Researchers’ Cancer Cell Mapping Technology Chosen for Anthropic AI for Science Project (newswise.com)
- Anthropic is running its own drug programs after acquiring a one-person biotech (qz.com)
- Is Zuckerberg pulling the rug out from under Anthropic? (Investing.com)
- Anthropic IPO Drug Discovery: 6 Partners [2026] (tech-insider.org)
- Anthropic plots IPO amid ongoing foray into drug development (Yahoo News)
- Anthropic heads toward Nasdaq debut, likely pricing above initial range
- Anthropic's share price lands at $83, above the range it had set
- Anthropic's IPO nears as AI jitters weigh on Wall Street
- Anthropic prepares Nov. 19 Nasdaq IPO as Nvidia's CEO resigns
- Anthropic pushes ahead with IPO as AI jitters rattle markets
- Anthropic's IPO and Nvidia's earnings loom over stock market
More from Technology & AI
- China puts humanoid robots to work serving food and sorting parcels
- Newsom proposes sweeping AI safety rules for Washington
- Google releases Gemini 4 Neon AI model with million-token context
- Microsoft and Intel widen their cloud chip partnership
- Google DeepMind rolls out Genie 4 to select subscribers
- AI helped AMD shorten chip design work, OpenAI says